SCHEMBL30765972

SCHEMBL30765972

COC(=O)Cc1c(F)ccc([N+](=O)[O-])c1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.43
FGFR1 P11362 1/20 0.43
PDGFRA P16234 1/20 0.43
FLT1 P17948 1/20 0.43
FGFR3 P22607 1/20 0.43
KDR P35968 1/20 0.43
LMNA P02545 6/20 0.40
RECQL P46063 1/20 0.40
TXNRD1 Q16881 1/20 0.39
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
ALDH1A1 P00352 3/20 0.38
PKM P14618 2/20 0.38
GSTP1 P09211 1/20 0.38
GSTM2 P28161 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
THRB P10828 1/20 0.37
ATM Q13315 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6284303 1.00 PDGFRB (0.43) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL6285685 0.87 PDGFRB (0.42) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL27972634 0.84 PDGFRB (0.42) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL31558555 0.83 CYP1A2 (0.45) LMNARECQLMEN1KMT2AALDH1A1
SCHEMBL6583252 0.83 CYP1A2 (0.45) LMNARECQLMEN1KMT2AALDH1A1
SCHEMBL30765782 0.81 ALDH1A1 (0.41) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL22655985 0.81 SMN1; SMN2 (0.44) LMNAMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL2975400 0.80 ATM (0.40) LMNARECQLMEN1KMT2AALDH1A1
SCHEMBL6697372 0.78 ALDH1A1 (0.38) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL4131823 0.77 ATM (0.47) PDGFRBFGFR1PDGFRAFLT1FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed